Resources

Pay changes and team-based care changed diabetes care.

A follow-up study has looked into long-term DM survival with hyperbaric-oxygen therapy...

Last Friday, the FDA -- after rejecting them once -- finally approved Novo's two new Insulins, Tresiba and Ryzodeg. (See article for details.) Do you feel comfortable in recommending either to your patients? Follow the link to respond.

64-year female presents to your office for her 3-month follow-up. She has previously been diagnosed with mild diastolic heart failure, secondary to hypertension. She currently takes an ace-inhibitor and a diuretic with good control of her heart failure symptoms and hypertension. At her last visit, she had a FPG 118 mg/dl. In a subsequent conversation with her, you discussed how she has developed prediabetes and suggested lifestyle modifications. Since her last visit, she has taken up very gentle walking four times/week and has changed her diet to a more healthful one. Despite these positive changes, this visit's labs return an A1C 7.8%; her remaining labs are within normal limits. Which one of the following antihyperglycemic medication classes would you choose to initiate treatment? A. Sulfonylureas B. Biguanides C. Insulin D. Thiazolidinediones For the complete question and answer, just follow the link!

Asian-Americans develop type 2 diabetes at lower BMI than the general population...

Higher cumulative doses and duration of glyburide may be associated with increased risk...

Orbera is a non-surgical intragastric balloon device that has been used for weight loss outside of the United States for over 20 years. It is now FDA approved to be used in the United States. The device is indicated for weight reduction in obese patients with a BMI of 30 to 40 kg/m2 who have been unable to lose weight with diet and exercise. The non-surgical procedure takes about 30 minutes. See Item #4

A bacterial species common to both diseases increases arterial inflammation by altering gene expression.

Findings suggest significant reduction in the risk of CV death and all-cause mortality for T2DM patients with a history of CVD.

Your patient has been taking metformin, glipizide and a daily basal insulin dose (.85 U/kg/day). While his fasting glucose levels are on target, he have not yet been able to reach his individualized glycemic target of A1C<7%. In your discussion with him about the addition of a prandial insulin dose to his regimen, you compare and contrast his options. Compared to basal insulin alone, premixed insulins: Follow link to give your answer!